Change called for in Phase II/III trials. (Sixteenth AIDS Clinical Trial Group Meeting)

Sixteenth AIDS Clinical Trial Group Meeting

Phase II/III clinical trials should provide a "user's manual" permitting the optimization of individual therapy, the vice chair of the ACTG Pharmacology Core Committee suggested.

Speaking at a plenary session of the recent Sixteenth NIAID AIDS Clinical Trial Group Meeting in Washington, D.C., Lewis Sheiner of the University of California, San Francisco, called for a fundamental change in the goals of Phase II/III clinical trials.

Sheiner suggested that Phase II/III trials should do something new: provide care providers with a "user's manual" for a drug so that treatment can be tailored to the needs of …